REGENXBIO INC. (NASDAQ:RGNX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On January4, 2018, REGENXBIO Inc. (the “Company”) issued a press release (the “Press Release”) regarding its operational highlights and financial condition for the year ended December31, 2017. The final subheading bullet of the Press Release and the section titled “Financial Guidance” of the Press Release are furnished in Exhibit99.1 to this Current Report on Form8-K and are incorporated by reference herein.

The information in Item 2.02 of this Current Report on Form8-K, along with the final subheading bullet of the Press Release and the section titled “Financial Guidance” of the Press Release, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

The Press Release also includes information regarding operational highlights of the Company for the year ended December31, 2017 and certain anticipated milestones and financial guidance of the Company for the year ending December31, 2018.

A copy of the Press Release is filed as Exhibit 99.1 to this Current Report on Form8-K and incorporated herein by reference, with the exception of the final subheading bullet of the Press Release and the section titled “Financial Guidance” of the Press Release, which are furnished as set forth in Item 2.02 above.

REGENXBIO Inc. Exhibit
EX-99.1 2 d445079dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   REGENXBIO Provides Year-End 2017 Corporate Update – Initiated third cohort dosing of RGX-314 Phase I clinical trial for wet AMD – – Initiated second cohort dosing of RGX-501 Phase I/II clinical trial for HoFH – – Anticipate completing dosing and presenting topline data from RGX-314 and RGX-501 trials in late 2018 – – Anticipate initiating dosing in clinical trials for MPS I and MPS II in first half 2018 – – Ended 2017 with greater than $175 million in cash,…
To view the full exhibit click here

About REGENXBIO INC. (NASDAQ:RGNX)

REGENXBIO Inc. is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Its NAV Technology Platform is applied in the development of approximately 30 product candidates for a range of diseases, including over five internally developed product candidates and approximately 20 partnered product candidates developed by its NAV Technology Licensees. Its therapeutic programs include RGX-501 for Homozygous familial hypercholesterolemia (HoFH); RGX-111 for Mucopolysaccharidosis Type I (MPS I); RGX-121 for Mucopolysaccharidosis Type II (MPS II); RGX-314 for Wet age related macular degeneration (wet AMD), and RGX-321 for X-linked retinitis pigmentosa (XLRP).